PVLA
Palvella Therapeutics, Inc. Common StockPVLA
PVLA
0
Funds holding %
of 7,398 funds
84
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
35.95% more ownership
Funds ownership: 0% [Q3] → 35.95% (+35.95%) [Q4]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$38
89%
upside
Avg. target
$44
117%
upside
High target
$50
149%
upside
6 analyst ratings
6 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Andrew Fein 28% 1-year accuracy 99 / 360 met price target | 89%upside $38 | Buy Reiterated | 1 Apr 2025 |
Stifel Annabel Samimy 33% 1-year accuracy 3 / 9 met price target | 124%upside $45 | Buy Initiated | 26 Mar 2025 |
Jones Trading Catherine Novack 10% 1-year accuracy 1 / 10 met price target | 124%upside $45 | Buy Initiated | 25 Mar 2025 |
Scotiabank Louise Chen 28% 1-year accuracy 36 / 128 met price target | 149%upside $50 | Sector Outperform Initiated | 7 Mar 2025 |
Canaccord Genuity Whitney Ijem 21% 1-year accuracy 9 / 43 met price target | 94%upside $39 | Buy Maintained | 26 Feb 2025 |
Financial journalist opinion
Based on 3 articles about PVLA published over the past 30 days
Neutral
GlobeNewsWire
5 days ago
Palvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress of Pediatric Dermatology
WAYNE, Pa., April 02, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or “the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced a late-breaking oral presentation at the upcoming 15th World Congress of Pediatric Dermatology, taking place April 8-11, 2025, in Buenos Aires, Argentina. The oral presentation will highlight SELVA, a 24-week, Phase 3, single-arm, baseline-controlled clinical trial of QTORIN™ rapamycin 3.9% anhydrous gel for the treatment of microcystic lymphatic malformations.
Neutral
GlobeNewsWire
1 week ago
Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update
Upon close of merger and $78.9mm concurrent private placement from a syndicate of leading healthcare-dedicated investors, completed transformation to a publicly traded rare disease biopharmaceutical company advancing a late clinical-stage pipeline and a platform for treating serious, rare genetic skin diseases
Neutral
GlobeNewsWire
2 weeks ago
Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025
WAYNE, Pa., March 18, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced that it will report its full year 2024 financial results on Monday, March 31, 2025.
Neutral
GlobeNewsWire
1 month ago
Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference
WAYNE, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced that its management team will present at the TD Cowen 45th Annual Healthcare Conference on Tuesday March 4, 2025, at 2:30 p.m. ET. A live webcast of the presentation will be available on the Events and Presentations section of Palvella's website at www.palvellatx.com.
Neutral
GlobeNewsWire
1 month ago
Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old
Expansion reflects Palvella's commitment to serving all patients affected by microcystic lymphatic malformations (microcystic LMs)
Neutral
GlobeNewsWire
3 months ago
Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 Million
Palvella Therapeutics to debut on Nasdaq under the ticker symbol “PVLA” as a publicly traded rare disease biopharmaceutical company advancing a late clinical-stage pipeline and a platform for treating serious, rare genetic diseases
Charts implemented using Lightweight Charts™